image description

Tag: lupus research alliance

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] Read More

Treat-to-Target is Feasible and Beneficial in Lupus

September 19, 2019 Treating patients with lupus until they reach specific health goals can reduce disease flares and prevent organ damage, according to a research team co-led by Professor Eric F. Morand, at Monash University in Australia and past recipient of the Distinguished Innovator Award from the Lupus Research Alliance (LRA). This study is important […] Read More

PALS Clinical Trial Program Opens at Five Universities

August 8, 2019 In five pilot cities, people with lupus who are thinking about taking part in a clinical trial can now join LRA’s Patient Advocates for Lupus Studies (PALS) program created by our affiliate Lupus Therapeutics. The program will pair adults with lupus interested in learning about clinical trials with a peer or “PAL” who […] Read More

LRA-Funded Discovery May Benefit Alzheimer’s Disease

August 1, 2019 A new study by LRA Distinguished Innovator Award recipient Dr. Douglas Green of St. Jude Children’s Research Hospital in Memphis, TN, and colleagues may have uncovered a new way to treat Alzheimer’s disease. The research, highlighted recently in Forbes magazine and published in the journal Cell, identified one of the brain’s mechanisms […] Read More

LRA Partners with Celgene on Cutting-Edge Research Projects

August 1, 2019 The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, is very pleased to announce a unique new partnership with Celgene Corporation that provides $3,000,000 for bold cutting-edge research projects.  This opportunity will focus on understanding the underlying mechanisms of disease, addressing lupus heterogeneity — how much […] Read More

Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.  Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] Read More

Novel Therapeutic Approaches & Translational Challenges

One session at our recent scientific conference Forum for Discovery was devoted to meeting the need for new approaches to lupus and the challenges faced in “translating” what is learned by researchers into therapies that will help patients with lupus. Gerald Nepom, MD, PhD, Co-Chair of LRFs Scientific Advisory Board and Director of the Benaroya Research […] Read More

LRA’s 2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz

Boston, MA. June 19, 2019. The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients […] Read More